zurück

Valoctocogene roxaparvovec (hemophilia A)

 

Subject:

  • Active Sustance: Valoctocogene roxaparvovec
  • Name: Roctavian®
  • Therapeutic area: Hemophilia A
  • Pharmaceutical company: BioMarin International Ltd.

 

Time table:

  • Start: 15.09.2022
  • Publication of assessment: 15.12.2022
  • End of public hearing: 05.01.2023
  • Final decision by G-BA: beginning of March 2023

 

Comparative therapy:

  • No comparative therapy due to orphan drug designation